Levomilnacipran HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 314246

CAS#: 175131-60-9 (HCl)

Description: Levomilnacipran (brand name Fetzima) is an antidepressant approved for the treatment of major depressive disorder in the United States. It was developed by Forest Laboratories and Pierre Fabre Group, and was approved by the Food and Drug Administration in July 2013. Levomilnacipran is the levo- enantiomer of milnacipran, and has similar effects and pharmacology, acting as a serotonin-norepinephrine reuptake inhibitor (SNRI). (Source: http://en.wikipedia.org/wiki/Levomilnacipran)

Chemical Structure

Levomilnacipran HCl
CAS# 175131-60-9 (HCl)

Theoretical Analysis

MedKoo Cat#: 314246
Name: Levomilnacipran HCl
CAS#: 175131-60-9 (HCl)
Chemical Formula: C15H23ClN2O
Exact Mass:
Molecular Weight: 282.812
Elemental Analysis: C, 63.70; H, 8.20; Cl, 12.53; N, 9.91; O, 5.66

Price and Availability

Size Price Availability Quantity
100.0mg USD 150.0 Same day
200.0mg USD 250.0 Same day
500.0mg USD 350.0 Same day
1.0g USD 450.0 Same day
2.0g USD 550.0 Same day
5.0g USD 950.0 Same day
10.0g USD 1650.0 Same day
50.0g USD 3650.0 Same day
100.0g USD 5650.0 2 Weeks
Click to view more sizes and prices
Bulk inquiry

Related CAS #: 175131-60-9 (HCl)   96847-55-1 (free base)  

Synonym: F2695 hydrochloride; F2695; F 2695; F-2695; Levomilnacipran; Levomilnacipran HCl; Brand name: Fetzima.

IUPAC/Chemical Name: (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide hydrochloride


InChi Code: InChI=1S/C15H22N2O.ClH/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12;/h5-9,13H,3-4,10-11,16H2,1-2H3;1H/t13-,15+;/m0./s1

SMILES Code: O=C([C@]1(C2=CC=CC=C2)[C@H](CN)C1)N(CC)CC.Cl.

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO.

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 282.812 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Deardorff WJ, Grossberg GT. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. Expert Opin Pharmacother. 2014 Sep 16:1-18. [Epub ahead of print] PubMed PMID: 25224953.

2: Montgomery SA, Gommoll CP, Chen C, Greenberg WM. Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials. CNS Spectr. 2014 Jun 5:1-9. [Epub ahead of print] PubMed PMID: 24902007.

3: Palmer EC, Binns LN, Carey H. Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder. Ann Pharmacother. 2014 May 8;48(8):1030-1039. [Epub ahead of print] Review. PubMed PMID: 24811398.

4: Wang ZJ, Renata H, Peck NE, Farwell CC, Coelho PS, Arnold FH. Improved cyclopropanation activity of histidine-ligated cytochrome P450 enables the enantioselective formal synthesis of levomilnacipran. Angew Chem Int Ed Engl. 2014 Jun 23;53(26):6810-3. doi: 10.1002/anie.201402809. Epub 2014 May 6. PubMed PMID: 24802161; PubMed Central PMCID: PMC4120663.

5: Chen L, Boinpally R, Greenberg WM, Wangsa J, Periclou A, Ghahramani P. Effect of hepatic impairment on the pharmacokinetics of levomilnacipran following a single oral dose of a levomilnacipran extended-release capsule in human participants. Clin Drug Investig. 2014 May;34(5):351-9. doi: 10.1007/s40261-014-0182-5. PubMed PMID: 24677141.

6: Sambunaris A, Gommoll C, Chen C, Greenberg WM. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials. Int Clin Psychopharmacol. 2014 Jul;29(4):197-205. doi: 10.1097/YIC.0000000000000033. PubMed PMID: 24667487; PubMed Central PMCID: PMC4047314.

7: Shiovitz T, Greenberg WM, Chen C, Forero G, Gommoll CP. A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder. Innov Clin Neurosci. 2014 Jan;11(1-2):10-22. PubMed PMID: 24653937; PubMed Central PMCID: PMC3960779.

8: Mago R, Mahajan R, Thase ME. Levomilnacipran: a newly approved drug for treatment of major depressive disorder. Expert Rev Clin Pharmacol. 2014 Mar;7(2):137-45. doi: 10.1586/17512433.2014.889563. PubMed PMID: 24524592.

9: Levomilnacipran (Fetzima) a new SNRI for depression. Med Lett Drugs Ther. 2013 Dec 23;55(1432):101-2. PubMed PMID: 24419243.

10: Saraceni MM, Venci JV, Gandhi MA. Levomilnacipran (Fetzima): A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder. J Pharm Pract. 2013 Dec 31;27(4):389-395. [Epub ahead of print] PubMed PMID: 24381243.